Shares of others in the race may lose momentum Companies working on COVID-19 treatment and prevention have seen their shares soar so far this year. Moderna (NASDAQ: MRNA) gained 44%, Regeneron Pharmaceuticals (NASDAQ: REGN) rose 15%, Gilead Sciences (NASDAQ: GILD) climbed 9%, and Inovio Pharmaceuticals (NASDAQ: INO) soared 102%.These stocks may lose momentum if chloroquine becomes the "go-to" drug for COVID-19. As mentioned above, there is room for additional treatments, but if chloroquine gets the first-mover advantage, others that eventually enter probably will seize a smaller share of the market than hoped. The news also would burst the bubble of...